Inspire Medical Systems reported second quarter 2026 revenue of $200.6 million, a 7.6% decrease from the prior year period, driven by U.S. headwinds in coding and reimbursement partially offset by international growth. The company raised its full-year 2026 revenue guidance to $835–$875 million and adjusted diluted EPS guidance to $1.05–$1.45. Management announced Project Horizon, a strategic restructuring plan expected to incur $20–$25 million in pre-tax charges to generate approximately $30 million in annualized growth investment capacity. Inspire Medical Systems operates in the medical technology industry, developing and commercializing minimally invasive neurostimulation solutions for obstructive sleep apnea.

Inspire Medical Systems, Inc. appointed Michael H. Carrel to its Board of Directors, effective July 20, 2026. Mr. Carrel will serve as a Class III director with a term expiring at the 2027 Annual Meeting and will join the Organization and Compensation Committee and the Quality, Product Supply and Technology Committee. Previously, Mr. Carrel served as President and CEO of AtriCure, Inc. and held leadership roles at Vital Images, Inc. and Zamba Corporation. His compensation includes an annual cash retainer of $55,000 for board service, additional retainers for committee service, and an initial $300,000 restricted stock unit award vesting over three years. Inspire Medical Systems, Inc. is a medical device company.

Casey M. Tansey notified the Company of his decision to retire from the Board of Directors, effective July 30, 2026. The retirement is not the result of any disagreement with the Company. Inspire Medical Systems is a medical technology company that develops and commercializes neurostimulation technology for obstructive sleep apnea.